SNGX · XBRL financial data

Soligenix financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (SNGX's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue	130	245*	117	2	0*	0*	—	—	—	—	—	—
Cost of revenue	110	222*	117	2	0*	0*	—	—	—	—	—	—
Gross profit	20	23*	—	—	—	0*	—	—	—	—	—	—
Research and development	826	778*	1,095	501	969	2,659*	2,227	1,677	1,584	2,283*	1,782	974
General and administrative	973	1,384*	1,022	1,244	897	1,054*	1,085	1,087	997	1,191*	1,103	1,125
Total operating expenses	1,799	2,161*	2,117	1,745	1,865	3,712*	3,312	2,764	2,580	3,475*	2,885	2,099
Operating income (loss)	(1,779)	(2,138)*	(2,117)	(1,745)	(1,865)	(3,712)*	(3,312)	(2,764)	(2,580)	(3,475)*	(2,885)	(2,099)
Other income (expense)	0*	0*	173	0	67	550*	(1)	(8)	(3)	(0)*	(2)	59
Income tax expense (benefit)	0*	(607)*	—	—	—	year only	—	—	—	year only	—	—
Net income (loss)	(1,663)	(1,820)*	(1,915)	(1,645)	(1,719)	(2,987)*	(3,237)	(2,702)	(2,531)	(2,896)*	(2,825)	(1,987)
Earnings per share, basic‡ USD per share	(2.56)	—	(2.88)	(1.31)	(0.78)	—	(1.06)	(0.82)	(0.58)	—	(0.28)	(0.12)
Earnings per share, diluted‡ USD per share	(2.56)	—	(2.88)	(1.31)	(0.78)	—	(1.06)	(0.82)	(0.58)	—	(0.28)	(0.12)
Weighted average shares, basic‡ thousands of shares	649	—	658	1,259	2,204	—	3,050	3,279	4,330	—	10,165	15,952
Weighted average shares, diluted‡ thousands of shares	649	—	658	1,259	2,204	—	3,050	3,279	4,330	—	10,165	15,952

‡ Per-share figures and share counts are adjusted for the 1-for-16 stock split (June 2024); filings made before it reported them unadjusted.

Fiscal quarters (SNGX's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	10,299	8,446	7,092	9,413	9,840	7,820	7,297	5,098	10,525	7,936	6,029	9,811
Total current assets	10,972	9,507	7,818	9,663	10,307	8,829	7,641	5,320	10,881	8,849	6,565	10,172
Property and equipment, net	14	12	10	9	7	6	6	8	8	9	8	7
Right-of-use asset	258	230	201	171	140	109	77	409	382	355	327	298
Total assets	11,303	9,797	8,058	9,865	10,477	8,966	7,746	5,761	11,294	9,236	6,923	10,499
Accounts payable	1,461	1,111	1,437	1,698	891	668	600	650	1,207	1,115	829	1,407
Accrued liabilities	2,387	2,418	2,603	1,702	1,363	2,359	3,404	2,783	2,031	1,982	2,630	2,060
Total current liabilities	5,522	6,152	7,211	6,355	4,530	4,848	—	3,629	3,422	3,699	3,619	3,672
Lease liability, non-current	144	112	79	46	12	—	—	303	274	244	213	182
Total liabilities	7,082	7,275	7,290	6,400	4,542	4,848	4,134	3,932	3,696	3,943	3,833	3,854
Accumulated deficit	(223,884)	(225,704)	(227,620)	(229,264)	(230,983)	(233,971)	(237,208)	(239,624)	(242,155)	(245,051)	(247,876)	(249,863)
Total stockholders' equity	4,221	2,522	768	3,465	5,935	4,118	3,612	1,829	7,598	5,292	3,090	6,646
Total liabilities and equity	11,303	9,797	8,058	9,865	10,477	8,966	7,746	5,761	11,294	9,236	6,923	10,499
Common shares outstanding (cover page)‡ thousands of shares	649	658	987	2,280	2,509	3,156	3,264	4,286	10,086	10,306	14,824	21,765

‡ Per-share figures and share counts are adjusted for the 1-for-16 stock split (June 2024); filings made before it reported them unadjusted.

Fiscal quarters (SNGX's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(1,663)	(1,820)*	(1,915)	(1,645)	(1,719)	(2,987)*	(3,237)	(2,702)	(2,531)	(2,896)*	(2,825)	(1,987)
Stock-based compensation	65	141*	60	58	57	156*	64	100*	104*	320*	121	116*
Net cash from operating activities	(2,686)*	(1,828)*	(1,342)	(1,918)*	(2,910)*	(2,233)*	(1,847)	(2,742)*	(2,933)*	(2,745)*	(2,358)	(1,707)*
Purchases of property and equipment	—	—	—	—	—	—	—	—	1*	2*	—	—
Net cash from investing activities	—	—	—	—	—	—	—	—	(1)*	(2)*	—	—
Net cash from financing activities	(175)*	(46)*	(9)	4,235*	3,293*	243*	1,325	546*	8,361*	158*	451	5,488*
Net change in cash	(2,862)*	(1,852)*	(1,355)	2,321*	428*	(2,021)*	(522)	(2,200)*	5,428*	(2,589)*	(1,907)	3,782*

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Soligenix	9,811	not reported	(1,707)*	21.8M	5.7 quarters	Q2 FY26 10-QJun 30, 2026
Target Group	14	1,381	(223)*	617.0M	0.1 quarters	Q2 FY26 10-QJun 30, 2026
Creative Medical Technology Holdings	8,714	0	(1,472)*	6.6M	5.9 quarters	Q2 FY26 10-QJun 30, 2026
Aspira Women's Health	477	17	(2,010)*	46.6M	0.2 quarters	Q2 FY26 10-QJun 30, 2026
Matinas BioPharma Holdings	761	not reported	(1,836)*	14.7M	0.4 quarters	Q2 FY26 10-QJun 30, 2026
Synlogic	13,183	0	(922)*	12.2M	14.3 quarters	Q2 FY26 10-QJun 30, 2026
China Pharma Holdings	305	948	(33)*	43.0M	9.3 quarters	Q2 FY26 10-QJun 30, 2026
Viskase Holdings	7,747	95,279	454*	14.3M	—	Q3 FY26 10-QSep 30, 2026
Xenetic Biosciences	6,472	661	(875)*	2.3M	7.4 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.